Clinical outcomes and risk factors of thromboprophylaxis with rivaroxaban versus aspirin in patients undergoing hip arthroplasty in low-incidence population: A nationwide study in Korea.

Hong Ah KimJu-Yeun LeeSo Hyun ParkJiEun KangKyung Suk ChoiSandy Jeong Yeon Rhie

Published in: Pharmacoepidemiology and drug safety (2019)

This study demonstrates that rivaroxaban was more effective in preventing VTE following hip arthroplasty without raising bleeding risks in clinical settings. Age more than or equal to 80 years, women, and a history of thromboembolism were the risk factors of VTE incidence.

Keyphrases

venous thromboembolism
risk factors
direct oral anticoagulants
patients undergoing
atrial fibrillation
total hip arthroplasty
low dose
pulmonary embolism
cardiovascular events
type diabetes
adipose tissue
antiplatelet therapy
pregnant women
risk assessment
acute coronary syndrome
climate change
pregnancy outcomes